Cart
sales@molnova.com
JI069
CAS No. 850019-35-1
JI069( —— )
Catalog No. M37038 CAS No. 850019-35-1
JI069 (WAY-354189) is a potent STAT3 inhibitor that inhibits gp130 signaling by inducing dissociation between gp130 and JAK1.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 38 | In Stock |
|
| 10MG | 57 | In Stock |
|
| 25MG | 107 | In Stock |
|
| 50MG | 172 | In Stock |
|
| 100MG | 276 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameJI069
-
NoteResearch use only, not for human use.
-
Brief DescriptionJI069 (WAY-354189) is a potent STAT3 inhibitor that inhibits gp130 signaling by inducing dissociation between gp130 and JAK1.
-
DescriptionJI069 (WAY-354189) is a potent STAT3 inhibitor that inhibits gp130 signaling by inducing dissociation between gp130 and JAK1.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayJAK/STAT Signaling
-
TargetSTAT
-
RecptorSTAT | JAK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number850019-35-1
-
Formula Weight387.24
-
Molecular FormulaC15H12Cl2N2O4S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(N)C=1C=CSC1NC(=O)COC(=O)CC=2C(Cl)=CC=CC2Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
LLL3
LLL3 is a structural analogue of STA-21 that acts as a novel STAT3 inhibitor.
-
STAT5 inhibitor 17f
A novel potent, selective inhibitor of phosphorylation and transcriptional activity of STAT5, but not STAT3, AKT, or Erk1/2 phosphorylation.
-
Palivizumab
Palivizumab (MEDI 493) is a humanized RSV-specific monoclonal antibody that selectively inhibits epitopes at the F protein A antigenic site of RSV subtypes A and B for the prevention of respiratory syncytial virus infection (RSV).
